Urologic Oncology: Seminars and Original Investigations
Издатель: Elsevier · ISSN 1078-1439 · 64 статей
- Is all gross hematuria high risk? Age-stratified outcomes after anticoagulation initiation using a large claims database
- FOXD1 upregulates DARS2-mediated glycolysis to drive cisplatin resistance in bladder cancer
- Intraoperative indocyanine green fluorescence guidance to reduce ureteroenteric anastomotic strictures during robot-assisted radical cystectomy. A systematic review and meta-analysis
- CDKL1 facilitates tumorigenesis and metastasis of bladder urothelial carcinoma by activating SIRT1/Wnt/β-catenin signaling
- Performance of the EORTC and CUETO risk prediction models in contemporary patients undergoing transurethral resection of bladder tumor with blue light cystoscopy
- Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank
- Perioperative and survival outcomes of synchronous vs. metachronous upper tract urothelial carcinoma among bladder cancer patients treated with radical cystectomy and nephroureterectomy: Results from an International Multicenter Collaborative Study—On behalf of the Young Academic Urology (YAU) Urothelial Working Group
- Development and internal validation of machine-learning models to predict adverse pathological features in upper tract urothelial carcinoma
- Clinical characteristics and oncological outcomes of upper tract urothelial carcinoma in patients with personal or family history of Lynch-syndrome-associated cancers
- Cryoablation for localized prostate cancer: Feasibility in large prostates
- Incidental bladder cancer detected by routine cystoscopy before robot-assisted radical prostatectomy: A multicenter retrospective study
- Epidemiological trends in penile cancer and the evolving role of dynamic sentinel lymph node biopsy
- Corrigendum to “A 2-center review of histopathology of variants of upper urinary tract urothelial carcinoma and their impact on clinical outcomes” [Urologic Oncology: Seminars and Original Investigations 42 (2024) 333.e15−333.e20]
- Corrigendum to “Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition” Volume 35, Issue 10, October 2017, Pages 593-599
- The role of lymph node dissection in upper tract urothelial carcinoma
- Benign but burdensome: Complications and management of benign prostatic hyperplasia during active surveillance of prostate cancer in a large cohort
- Predicting long-term metastatic risk after radical prostatectomy: Adding Genomic Prostate Score, grade group, and cribriform size to unfavorable histology burden translates into minimal incremental discrimination
- Quantitative core-level tumor burden and grading in MRI-targeted vs. systematic prostate biopsy: A within-patient paired analysis
- Intraductal carcinoma of the prostate does not independently predict adverse outcomes after radical prostatectomy: A National Cancer Database analysis
- Comparison and interpretability of machine learning algorithms to predict survival of patients with prostate cancer
- Prostate lymphoma uncovered during urological encounters: Diagnostic challenges and clinical outcomes in a case series with systematic review of the literature
- FOCS-24: An integrated oncologic–functional endpoint and its preoperative nomogram after focal therapy for localized prostate cancer
- Second primary cancer risk after penile squamous cell carcinoma: A population-based study
- Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care
- Nonmuscle-invasive bladder cancer after solid organ transplantation: Clinical outcomes and recurrence patterns
- Impact of second-look TURBT on high grade recurrence and intravesical therapy in high-risk non–muscle-invasive bladder cancer: A 20-year experience
- Retraction notice to “Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility” [Urologic Oncology: Seminars and Original Investigations 31 (2013) 1193–1203]
- Response to “Calendar-time bias in a TriNetX study of GLP-1 receptor agonists, SGLT2 inhibitors and bladder cancer survival”
- Translational research models for variant subtype bladder cancers: A comprehensive review of the current landscape
- Beyond KEYNOTE-564 eligibility: A clinical decision aid to refine selection for adjuvant pembrolizumab in clear cell renal cell carcinoma